Ordspono (Odronextamab)

Odronextamab, the active ingredient in Ordspono, is a monoclonal antibody presented as a solution for intravenous infusion use. It targets malignant B‑cell populations and is indicated for certain hematologic cancers in adult patients. GNH USA supplies Ordspono as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Ordspono as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ordspono is a bispecific antibody that engages the CD20 antigen on B‑cells and ​        ​    ​   ​   ​   ​   ​    ​  ​  ​  ​  ​  ​  ​  ​  ​ ‑            ‑  ‑  ‑  ‑  ‑